MediXall Group, Inc.
MDXL · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -26.5% | -55.3% | 25% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 57.4% | 72.4% | 57.3% | 48.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | -773.4% | -719.2% | -259.1% | -1,036.1% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$0 | -$0 | -$1 |
| % Margin | 678.9% | -919.5% | -411.9% | -1,539.2% |
| EPS | 0.001 | -0.004 | -4.2 | -0.012 |
| % Growth | 134.1% | 99.9% | -35,493.2% | – |
| EPS Diluted | 0.001 | -0.004 | -4.2 | -0.012 |
| Weighted Avg Shares Out | 162 | 139 | 134 | 130 |
| Weighted Avg Shares Out Dil | 162 | 139 | 134 | 130 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$0 | -$0 | -$0 | -$1 |
| % Margin | -771.4% | -717.5% | -258.2% | -1,036.1% |